Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: P.M.Freedman who wrote (1012)	6/11/1999 2:19:00 PM
From: SDR-SI	Respond to of 1686

Mr. Freedman, As an added note to my Annual Meeting comments, there was nothing indicated that that would give anyone even the slightest suspicion that anything you have said or alleged might have even the slightest hint of credibility. Your comments, as clearly reflected in your post referenced above, might seem to suggest some agenda other than objective analysis. JMHO Steve

To: P.M.Freedman who wrote (1012)	6/11/1999 3:33:00 PM
From: FiloF	Respond to of 1686

I think you might want to look at a chart -- the "decline of the stock" doesn't exist. If you are talking about the recent decline, do you think BGEN just all of a sudden decided to split the stock????

To: P.M.Freedman who wrote (1012)	6/11/1999 5:13:00 PM
From: Harold Engstrom	Respond to of 1686

PMF, just a couple of quick points. Firstly, Biogen stock is not in decline. Its earnings have been growing at a fast pace; its balance sheet is tremendous; its pipeline is of extremely high quality, is maturing and growing. These things have propelled it from $30 to its current price over the past two years. Biogen is showing its investors a focused management approach and resulting increasing earnings. Secondly, the reasoning in your prior post was incomprehensible. It was unclear what the basis for your conclusions was. Beta interferon as a treatment for MS is not new. The market has growth significantly since Avonex was introduced and is continuing to grow. I think that Biogen is the best biopharm value and growth story that is out there. Certainly, there are some small biotech companies that may see greater price appreciation in the short term, but as far as risk/reward goes... this company is your best bet. It is nice to see contrarian opinions on this board for a change. But, it would be even nicer to see opinions with more solid basis. Look forward to seeing more of your thoughts in the future.